InfuSystem Holdings Inc

Aktienanalyse zu InfuSystem Holdings Inc (INFU)

$13.150

+0.359 (+2.73%)Zum Schluss

Loading chart…
Hoch
13.590
Eröffnung
13.140
Volumengewichteter Durchschnittskurs
13.21
Volumen
134.96K
Marktkap.
145.87M
Tief
12.895
Umsatz
1.78M
EV/EBITDA, TTM
9.35

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

ir.infusystem.com

KI-Analyse of InfuSystem Holdings Inc (INFU)

Kaufen

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

Bewertungskennzahlen

Das aktuelle erwartete KGV von InfuSystem Holdings Inc (INFU) beträgt 22.73, verglichen mit dem 5-Jahres-Durchschnitt von 68.23.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
68.23
Aktuelles P/E
22.73
Überbewertet
139.38
Unterbewertet
-2.92

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
8.84
Aktuelles EV/EBITDA
9.35
Überbewertet
11.12
Unterbewertet
6.56

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
1.43
Aktuelles P/S
1.70
Überbewertet
1.88
Unterbewertet
0.98

Alphio-AI-Kursszenarien für INFU

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%INFU

$7.68

Szenariopreis

B

Basis

Basis · 50%INFU

$6.54

Szenariopreis

B

Bärisch

Bärisch · 25%INFU

$6.33

Szenariopreis

Event-Zeitleiste

2026-08-04 (ET)

07:00:00

Sees 2026 Adjusted EBITDA Margin in Mid to Low 20%'s

07:00:00

Company Reports Q2 Revenue of $36.9M

2026-05-18 (ET)

16:40:00

InfuSystem Approves $20M Stock Repurchase Program

2026-05-07 (ET)

07:30:00

Q1 Revenue at $33.7M, Below Consensus

2026-03-02 (ET)

09:40:00

InfuSystem Trading Resumes

News

INFU FAQ – beantwortet von Alphio AI

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln